- In March 2024, the FDA approved Wegovy for cardiovascular risk reduction based on the SELECT trial
- The SELECT trial showed a 20% reduction in major adverse cardiovascular events in 17,604 patients
- This creates a separate insurance pathway — even for plans that exclude weight loss medications
- Qualifying patients must have established CVD and a BMI of 27 or higher
The SELECT trial
In March 2024, the FDA approved a supplemental indication for Wegovy (semaglutide 2.4mg): the reduction of cardiovascular risk in adults with established cardiovascular disease and either obesity or overweight. This approval was based on the results of the SELECT trial — one of the most significant cardiovascular outcome studies in recent years.
Here are the key numbers from the trial:
| SELECT trial data point | Result |
|---|---|
| Total participants | 17,604 |
| Study design | Randomized, double-blind, placebo-controlled |
| Reduction in MACE (heart attack, stroke, CV death) | 20% |
| Average weight loss | 9.4% of body weight |
| Patient population | Adults with established CVD, BMI ≥27, without type 2 diabetes |
| Mean follow-up period | 39.8 months |
MACE stands for major adverse cardiovascular events — a composite endpoint that includes heart attack, stroke, and cardiovascular death. A 20% reduction in these events is clinically significant and represents a meaningful improvement in patient outcomes.
The SELECT trial was not a weight loss study. It was a cardiovascular outcomes trial. The fact that it also produced weight loss is secondary to its primary finding: semaglutide reduces heart attacks, strokes, and cardiovascular death.
Who qualifies?
The FDA’s cardiovascular indication for Wegovy applies to a specific patient population. To qualify, you must meet all of the following criteria:
- Established cardiovascular disease. This means you have a documented history of at least one of the following: heart attack (myocardial infarction), stroke (cerebrovascular accident), or peripheral artery disease (PAD).
- BMI of 27 or higher. Note that this is a lower threshold than the weight management indication (which requires BMI ≥30 or BMI ≥27 with comorbidities). For the cardiovascular indication, BMI ≥27 alone is sufficient when combined with established CVD.
- Age 18 or older. The indication applies to adults only.
The SELECT trial specifically enrolled patients without type 2 diabetes. While the FDA indication does not explicitly exclude diabetic patients, the trial data that supports the indication was generated in a non-diabetic population. If you have type 2 diabetes, your clinician may consider other pathways or additional evidence when prescribing under this indication.
Your clinician will evaluate your cardiovascular history, current risk factors, and overall health profile to determine whether the cardiovascular indication is appropriate for your situation. This is a clinical decision — not just a checkbox exercise.
Why this matters for insurance
The cardiovascular indication fundamentally changes the insurance conversation for eligible patients. Here is why:
When Wegovy is prescribed for weight loss, it is categorized as an anti-obesity medication. Many insurance plans exclude this category entirely, or subject it to extensive prior authorization, step therapy, and formulary restrictions.
When Wegovy is prescribed for cardiovascular risk reduction, it enters a different category. Cardiovascular medications are a core component of virtually every insurance formulary. Plans that would never cover a “weight loss drug” routinely cover cardiovascular therapies — because heart disease is the leading cause of death in the United States, and reducing cardiovascular risk is universally recognized as medically necessary.
This does not mean automatic coverage. Insurers are still developing their coverage policies for this specific indication. But the regulatory framework has changed. Wegovy is no longer just a weight loss medication — it is also a cardiovascular risk reduction medication. That distinction creates options that did not exist before March 2024.
Some plans that explicitly exclude weight loss medications have begun covering Wegovy under their cardiovascular formulary. Others have not yet updated their policies. Things are evolving, and the trajectory is toward broader coverage as more insurers incorporate the SELECT trial data into their formulary decisions.
How coverage works
When your clinician prescribes Wegovy under the cardiovascular indication, the prior authorization process looks different from a weight management PA. Here is what insurers typically require:
- Documentation of established CVD. Your clinician must provide medical records showing a prior heart attack, stroke, or peripheral artery disease diagnosis. This typically includes hospital records, imaging studies, or cardiology consultation notes.
- Current BMI documentation. A BMI of 27 or higher must be documented at the time of the prescription.
- Cardiovascular risk assessment. Some insurers require additional documentation of ongoing cardiovascular risk factors (hypertension, dyslipidemia, etc.).
- Clinical rationale. Your clinician writes a letter explaining why Wegovy is being prescribed for cardiovascular risk reduction, citing the SELECT trial data and your specific clinical situation.
The key difference is the framing. Instead of submitting a PA for an “anti-obesity medication,” your clinician submits a PA for a “cardiovascular risk reduction medication.” The medication is the same. The clinical justification is different.
We have been submitting cardiovascular indication PAs since the approval. Our clinical team understands what insurers are looking for, how to document the cardiovascular history effectively, and how to distinguish this submission from a standard weight management PA. The framing matters more than you might think.
Not everyone qualifies
The cardiovascular indication is powerful, but it has a specific scope. You must have established cardiovascular disease — not just risk factors. Having high blood pressure, high cholesterol, or a family history of heart disease does not meet the threshold. You need a documented cardiovascular event or peripheral artery disease diagnosis.
If you do not qualify for the cardiovascular indication, there are other pathways to explore:
- Standard weight management indication. If your plan covers anti-obesity medications, the weight management PA is the most direct route.
- Sleep apnea indication (Zepbound). If you have documented obstructive sleep apnea, tirzepatide may be covered under that indication.
- Diabetes pathway. If you have type 2 diabetes, semaglutide or tirzepatide may be prescribed under their diabetes indications (Ozempic or Mounjaro).
The weight loss still happens
An important point: prescribing Wegovy under the cardiovascular indication does not change what the medication does in your body. You still receive the full effects of semaglutide 2.4mg — including appetite regulation, metabolic improvement, and weight loss.
In the SELECT trial, participants lost an average of 9.4% of their body weight. This is somewhat less than the approximately 15% seen in the STEP 1 weight management trial, likely because the SELECT population had different baseline characteristics and the primary endpoint was cardiovascular, not weight loss.
The cardiovascular benefits and weight loss benefits are not mutually exclusive. You receive both, regardless of which indication appears on the prescription. The clinical management is the same — gradual dose titration, regular monitoring, nutrition support, and ongoing care.
What we do at PEAK
At PEAK, we evaluate every patient’s full clinical picture — not just their weight. If you have a cardiovascular history that qualifies for the SELECT-based indication, we will identify that pathway and pursue it.
Here is our process:
- Full evaluation. During your initial visit, we review your full medical history, including cardiovascular events, hospitalizations, and current risk factors.
- Pathway identification. We determine which FDA indication(s) apply to your situation and which one offers the strongest coverage pathway with your specific insurer.
- Benefits verification. Our insurance team checks your plan’s coverage for Wegovy under both the weight management and cardiovascular indications.
- PA submission. We prepare and submit the prior authorization with the documentation framework that matches the indication — cardiovascular records for the CV indication, weight management documentation for the obesity indication.
- Ongoing care. Regardless of which indication provides coverage, your treatment plan is the same — full, clinician-led weight management with regular monitoring and support.
Common questions
Does the cardiovascular indication cost less than the weight loss indication?
The medication itself is the same price regardless of indication. The difference is in insurance coverage. If your plan covers Wegovy under the cardiovascular indication but not the weight management indication, your out-of-pocket cost will be lower because your insurance is paying part of the cost.
Can my cardiologist prescribe Wegovy under this indication?
Yes. Any appropriately licensed prescriber can prescribe Wegovy under the cardiovascular indication. At PEAK, our clinicians coordinate with your cardiologist when appropriate to ensure continuity of care.
What if my insurer has not updated their policy yet?
Some insurers have been slow to create a separate coverage pathway for the cardiovascular indication. If your insurer denies the PA, we can request a peer-to-peer review, file a formal appeal citing the SELECT trial data, or explore alternative pathways while the appeal is in process.
Is the cardiovascular indication just a way to get around weight loss exclusions?
No. The cardiovascular indication is a separate, FDA-approved use of semaglutide based on rigorous clinical trial data showing a meaningful reduction in heart attacks, strokes, and cardiovascular death. Using this pathway requires a genuine cardiovascular diagnosis. At PEAK, we always prescribe based on clinical appropriateness, not insurance strategy alone.
Important safety information: Wegovy carries a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. It is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss your full medical history with your clinician before starting treatment.
PEAK accepts commercial insurance and TRICARE. We do not accept Medicare or Medicaid, including Medicare Advantage and Medicaid managed care plans.
